New advances in acute pancreatitis

Current Opinion in Gastroenterology

Volumn 23, Issue 5, 2007, Pages 494-501

  DiMagno, Matthew J ^a   DiMagno, Eugene P ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Acute pancreatitis; English language

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABEXATE; GLYCERYL TRINITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; POTASSIUM; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; TRANSFERRIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; ULINASTATIN;

ACUTE PANCREATITIS; ANTIBIOTIC PROPHYLAXIS; CHEMOPROPHYLAXIS; CHOLELITHIASIS; CHRONIC PANCREATITIS; DISEASE SEVERITY; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERIC FEEDING; GALLSTONE; GENE MUTATION; HUMAN; IATROGENIC DISEASE; MEDICAL LITERATURE; MORTALITY; MULTIPLE ORGAN FAILURE; PANCREAS NECROSIS; PARENTERAL NUTRITION; PREDICTION; RARE DISEASE; RECURRENT DISEASE; REVIEW; RISK FACTOR;

ACUTE DISEASE; ANIMALS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; ENTERAL NUTRITION; HUMANS; PANCREATITIS; PARENTERAL NUTRITION; RISK FACTORS;

EID: 34548412172     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282ba566d     Document Type: Review

References (62)

1. ••], the incidence of alcoholic pancreatitis (in non-UK countries) increased greater than biliary pancreatitis.
2. ••], the incidence of biliary pancreatitis increased greater than alcoholic pancreatitis.
3. Perez-Mateo M. How we predict the etiology of acute pancreatitis. JOP 2006; 7:257-261. The author reviews diagnostic tools to identify the etiology of acute pancreatitis, including measuring carbohydrate-deficient transferrin (CDT) to detect an excessive consumption of alcohol.
4. Ko CW. Risk factors for gallstone-related hospitalization during pregnancy and the postpartum. Am J Gastroenterol 2006; 101:2263-2268. This retrospective case controlled study reported that hospitalization for gallstone associated diseases related to pregnancy occurs in approximately 0.5% of all births. Risk was higher for Native Americans and for women who were younger, overweight or obese.
5. Debray FG, Drouin E, Herzog D, et al. Recurrent pancreatitis in mitochondrial cytopathy. Am J Med Genet A 2006; 140:2330-2335.
6. Wilcox CM, Varadarajulu S, Eloubeidi M. Role of endoscopic evaluation in idiopathic pancreatitis: a systematic review. Gastrointest Endosc 2006; 63:1037-1045.
7. Bhatia V, Garg PK, Tandon RK, Madan K. Endoscopic retrograde cholangiopancreatography-induced acute pancreatitis often has a benign outcome. J Clin Gastroenterol 2006; 40:726-731. Post-ERCP acute pancreatitis occurs in approximately 10% and may be severe. In contrast, a prospective study of 1497 consecutive de novo ERCP procedures showed that post-ERCP acute pancreatitis occurred in only 3.8% and 95% had mild disease.
8. Eloubeidi MA, Tamhane A, Varadarajulu S, Wilcox CM. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc 2006; 63:622-629. This prospective cohort study showed that in 355 consecutive patients who underwent EUS-FNA of a solid pancreatic mass over a 42-month period, the incidence of acute pancreatitis is very low (0.85%) and mild.
9. Singh S, Loke YK. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf 2006; 29:1123-1132.
10. Thisted H, Jacobsen J, Munk EM, et al. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther 2006; 23:185-190.
11. Sorensen HT, Jacobsen J, Norgaard M, et al. Newer cyclo-oxygenase-2 selective inhibitors, other nonsteroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther 2006; 24:111-116.
12. Eland IA, Sundstrom A, Velo GP, et al., Group ESGotEPR. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol 2006; 41:1484-1490. This multicenter population-based European case-control study reported that some antihypertensives moderately increase the risk of acute pancreatitis (ACE inhibitors and calcium channel blockers) and other pose no significant risk (loop diuretics, thiazides, potassium sparing diuretics).
13. Sundstrom A, Blomgren K, Alfredsson L, Wiholm BE. Acid-suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis: results from a Swedish Case-Control Study. Pharmacoepidemiol Drug Saf 2006; 15:141-149.
14. Norgaard M, Jacobsen J, Ratanajamit C, et al. Valproic acid and risk of acute pancreatitis: a population-based case-control study. Am J Ther 2006; 13:113-117.
15. ••].
16. Moreau JA, Zinsmeister AR, Melton LJD, DiMagno EP. Gallstone pancreatitis and the effect of cholecystectomy: a population-based cohort study. Mayo Clin Proc 1988; 63:466-473.
17. Jacob L, Geenen JE, Catalano MF, Geenen DJ. Prevention of pancreatitis in patients with idiopathic recurrent pancreatitis: a prospective nonblinded randomized study using endoscopic stents. Endoscopy 2001; 33:559-562.
18. Yusoff IF, Raymond G, Sahai AV. A prospective comparison of the yield of EUS in primary vs. recurrent idiopathic acute pancreatitis. Gastrointest Endosc 2004; 60:673-678.
19. Fogel EL, Toth TG, Lehman GA, et al. Does endoscopic therapy favorably affect the outcome of patients who have recurrent acute pancreatitis and pancreas divisum? Pancreas 2007; 34:21-45. A bi-part panel comprehensively appraised available data on idiopathic pancreatitis in patients with pancreas divisum and normal ducts and argued for or against the use of endoscopic therapy for patients.
20. Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994; 107:1481-1487.
21. Mullhaupt B, Truninger K, Ammann R. Impact of etiology on the painful early stage of chronic pancreatitis: a long-term prospective study. Z Gastroenterol 2005; 43:1293-1301.
22. Lankisch PG, Lohr-Happe A, Otto J, Creutzfeld W. Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion 1993; 54:148-155.
23. Pezzilli R, Morselli-Labate AM, Mantovani V, et al. Mutations of the CFTR gene in pancreatic disease. Pancreas 2003; 27:332-336.
24. Choudari CP, Imperiale TF, Sherman S, et al. Risk of pancreatitis with mutation of the cystic fibrosis gene. Am J Gastroenterol 2004; 99:1358-1363.
25. Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339:653-658.
26. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339:645-652.
27. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 2005; 118:372-381.
28. Steinberg WM, Chari ST, Forsmark CE, et al. Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas 2003; 27:103-117.
29. Alazmi WM, Fogel EL, Schmidt S, et al. ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative. Gastrointest Endosc 2006; 63:234-239.
30. Evans WB, Draganov P. Is empiric cholecystectomy a reasonable treatment option for idiopathic acute pancreatitis? Nat Clin Pract Gastroenterol Hepatol 2006; 3:356-357.
31. Martinez J, Johnson CD, Sanchez-Paya J, et al. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006; 6:206-209. A meta-analysis of 739 patients from five clinical studies confirmed that obese persons with acute pancreatitis have a greater probability of developing complications and severe disease and die more frequently than nonobese subjects.
32. Papachristou GI, Papachristou DJ, Morinville VD, et al. Chronic alcohol consumption is a major risk factor for pancreatic necrosis in acute pancreatitis. Am J Gastroenterol 2006; 101:2605-2610. Patients with acute pancreatitis were prospectively studied with contrast-enhanced CT. Alcohol intake of even moderate quantities significantly increased the risk of developing pancreatic necrosis regardless of the cause of acute pancreatitis.
33. Spitzer AL, Barcia AM, Schell MT, et al. Applying Ockham's razor to pancreatitis prognostication: a four-variable predictive model. Ann Surg 2006; 243:380-388.
34. •]. In a retrospective analysis of 265 patients with acute pancreatitis, a computermodel used kernel logistic regression and bootstrapping of 8 variables and was superior to APACHE II for predicting severity on admission.
35. •]. A retrospective analysis of patients with acute pancreatitis, showed that an artificial neural network more accurately assessed severity and mortality than APACHE II and Glasgow scoring systems.
36. ••].
37. Mofidi R, Duff MD, Wigmore SJ, et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg 2006; 93:738-744. A retrospective analysis of 759 patients with acute pancreatitis (between 2000 and 2004) showed that persistent SIRS was associated with MODS and death.
38. Rau BM, Bothe A, Kron M, Beger HG. Role of early multisystem organ failure as major risk factor for pancreatic infections and death in severe acute pancreatitis. Clin Gastroenterol Hepatol 2006; 4:1053-1061. In patients with sterile pancreatic necrosis who had a necrosectomy or nonoperative management, the major factors for developing pancreatic infection after operation were extent of necrosis and early MODS. Death was related to MODS rather than necrosis or infection, which contrasts with earlier findings in a larger cohort [39].
39. Götzinger P, Sautner T, Kriwanek S, et al. Surgical treatment for severe acute pancreatitis: extent and surgical control of necrosis determine outcome. World J Surg 2002; 26:474-478.
40. Milewski J, Rydzewska G, Degowska M, et al. N-acetylcysteine does not prevent postendoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 2006; 12:3751-3755.
41. Thomopoulos KC, Pagoni NA, Vagenas KA, et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006; 64:726-731.
42. Li ZS, Pan X, Zhang WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007; 102:46-51.
43. Xiong GS, Wu SM, Zhang XW, Ge ZZ. Clinical trial of gabexate in the prophylaxis of postendoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 2006; 39:85-90.
44. Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on postendoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006; 21:1065-1069.
45. Kaffes AJ, Bourke MJ, Ding S, et al. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc 2006; 64:351-357.
46. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65:624-632. This updated meta-analysis of RCTS for chemoprevention of post-ERCP acute pancreatitis showed that somatostatin and gabexate are not effective [47].
47. Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2007; 7:6.
48. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15:965-972.
49. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55:470-475.
50. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7.
51. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography- induced pancreatitis. Br J Surg 2001; 88:1178-1182.
52. Moreto M, Zaballa M, Casado I, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc 2003; 57:1-7.
53. •,54].
54. Meier R, Ockenga J, Pertkiewicz M, et al. ESPEN guidelines on enteral nutrition: pancreas. Clin Nutr 2006; 25:275-284.
55. Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. Dig Surg 2006; 23:336-345. A RCT of early (within 72 h) enteral versus parenteral feeding for patients with severe acute pancreatitis shows that enteral feeding dramatically reduced persistent organ failure, pancreatic infectious complications and mortality.
56. Kumar A, Singh N, Prakash S, et al. Early enteral nutrition in severe acute pancreatitis: a prospective randomized controlled trial comparing nasojejunal and nasogastric routes. J Clin Gastroenterol 2006; 40:431-434.
57. Eckerwall GE, Axelsson JB, Andersson RG. Early nasogastric feeding in predicted severe acute pancreatitis: A clinical, randomized study. Ann Surg 2006; 244:959-965; discussion 965-957.
58. Lankisch PG, Lerch MM. The role of antibiotic prophylaxis in the treatment of acute pancreatitis. J Clin Gastroenterol 2006; 40:149-155.
59. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006; 93:674-684.
60. Manes G, Uomo I, Menchise A, et al. Timing of antibiotic prophylaxis in acute pancreatitis: a controlled randomized study with meropenem. Am J Gastroenterol 2006; 101:1348-1353.
61. DiMagno MJ, Lee SH, Hao Y, et al. A proinflammatory, antiapoptotic phenotype underlies the susceptibility to acute pancreatitis in cystic fibrosis transmembrane regulator (-/-) mice. Gastroenterology 2005; 129:665-681.
62. •].